Key result
Ambasilide and dofetilide significantly reduced defibrillation energy requirements by 17.7% and 21.9% respectively (P<0.05 vs placebo), with no significant difference between the two treatments.
Why the study?
Does specific vs nonspecific potassium current blockade reduce defibrillation energy requirements in an anesthetized canine model?
Does specific vs nonspecific potassium current blockade reduce defibrillation energy requirements in an anesthetized canine model?
p-value: p=<0.05
Specific and nonspecific potassium current blockade have comparable effects on reducing defibrillation energy requirements in a canine model.
Should not change clinical defibrillation practices; hypothesis-generating for potassium blockade effects in humans.
UNLABELLED: Block of delayed rectifier potassium current (IK) is known to decrease defibrillation energy requirements (DERs). We tested the hypothesis that there would be no difference in DER reduction with a nonspecific IK (IKr + IKs) blocker, ambasilide, and a specific IKr blocker, dofetilide. METHODS: An anesthetized canine model (n = 30) of internal transvenous defibrillation with biphasic shocks was used. Ambasilide (n = 9; dose: 4.8 mg/kg, then 9.6 mg/kg/hour), dofetilide (n = 10; dose: 10 (micrograms/kg, then 3.6 (micrograms/kg/hour), or matched placebo (n = 11) were administered. DERs (J) were determined in triplicate using an increment-decrement protocol at baseline and during each treatment. ECG intervals were measured at baseline and during each treatment. ANOVA with post-hoc Bonferroni test was used for statistical analysis. RESULTS: Ambasilide resulted in a +23.5 +/- 4.06% prolongation of the QTc interval, while dofetilide resulted in a +20.5% +/- 3.76% prolongation of the QTc interval. Thus, the two drugs resulted in comparable prolongation of the QTc interval (P < 0.05 compared to placebo). Both drugs significantly reduced the DER (-17.7% +/- 5.33% reduction by ambasilide, and -21.9% +/- 5.21% reduction by dofetilide, P < 0.05 compared to placebo). There was no difference in the magnitude of DER reduction between the two treatments. CONCLUSIONS: Administration of equipotent doses (as indicated by QTc changes) of ambasilide or dofetilide had comparable effects on DERs. Selectivity of IK blockade has no significant effect on the magnitude of reduction in DERs.
No takes yet. Share an insight, caveat, or question.
Mehdirad et al. (1999) studied Defibrillation energy requirement (n=30). Ambasilide and dofetilide vs. Matched placebo was evaluated on Defibrillation energy requirement (DER) (p=<0.05). Ambasilide and dofetilide significantly reduced defibrillation energy requirements by 17.7% and 21.9% respectively (P<0.05 vs placebo), with no significant difference between the two treatments.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: